CarboCode develops sphingolipids that are useful for the operation of the brain, skincare, and the development of babies.
CarboCode has raised $15.8M in total funding. The most recent round was Series C. The last funding was announced in December 2024.
CarboCode's investors include Iberis Capital.
CarboCode is headquartered in Konstanz, Germany.
CarboCode develops sphingolipids that are useful for the operation of the brain, skincare, and the development of babies.
CarboCode is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"CarboCode — Funding & Investors." VCBacked, December 4, 2024, https://www.vcbacked.co/company/carbocode. Accessed October 28, 2026.
VCBacked. (2024). CarboCode — Funding & Investors. Retrieved October 28, 2026, from https://www.vcbacked.co/company/carbocode
{{cite web |title=CarboCode — Funding & Investors |url=https://www.vcbacked.co/company/carbocode |website=VCBacked |access-date=October 28, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated